![NCI will form an ad hoc committee to review screening trials The future of ECOG-ACRIN's slowly-accruing TMIST is in question](https://cdn.cancerletter.com/media/2020/09/24200818/TMIST_4x3.jpg)
![NCI will form an ad hoc committee to review screening trials The future of ECOG-ACRIN's slowly-accruing TMIST is in question](https://cdn.cancerletter.com/media/2020/09/24200818/TMIST_4x3.jpg)
Cover Story
NCI's cancer screening trials may be falling victim to the COVID-19 pandemic.
In Brief
Clinical Roundup
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement. - At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago
- The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop